BioCentury | Apr 23, 2019
Company News

Fulcrum gets rights to GSK's shelved p38 kinase inhibitor

...coronary syndrome. Fulcrum is also evaluating preclinical compounds against three additional targets for muscle diseases: UTRN...
...Dystrophia myotonica-protein kinase; DUX4 - double homeobox 4; FXN (FRDA) - Frataxin; UTRN - Utrophin Chris...
BioCentury | Jun 29, 2018
Clinical News

Summit discontinues DMD program after Phase II miss

...well as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin (UTRN)...
...has exclusive rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit's UTRN...
...NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...
BioCentury | Jun 27, 2018
Clinical News

Summit craters after ending DMD program

...as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin UTRN...
...CIS) to Summit's UTRN modulator pipeline for DMD (see "Sarepta Gets Territorial Rights to Summit's Utrophin...
...to $129.27 Wednesday. Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Sarepta Therapeutics Inc. Summit Therapeutics plc Utrophin (UTRN)...
BioCentury | Jan 26, 2018
Clinical News

Summit's ezutromid reduces muscle damage in DMD

...in MRI leg muscle parameters and pharmacokinetics. Secondary endpoints include muscle regeneration biomarkers, change in UTRN...
...biopsies and safety. Top-line 48-week data are expected in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...Product: Ezutromid (SMT C1100) (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...
BioCentury | Jan 25, 2018
Clinical News

Summit's ezutromid reduces muscle damage in DMD

...long-term, extension phase. Top-line 48-week data are expected in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...has exclusive rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit’s UTRN...
...in the EU. On Thursday, Sarepta gained $1.83 to $67.61. Chris Lieu ezutromid SMT C1100 Sarepta Therapeutics Inc. Summit Therapeutics plc Utrophin (UTRN)...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...reduced disease symptoms by activating liver expression of IL-10 or klotho, PDX1, and klotho or UTRN...
...the two-vector system reduced DMD symptoms after birth by activating the muscle regulators FST or UTRN...
...and duodenal homeobox 1 RELA (p65) - v-rel reticuloendotheliosis viral oncogene homolog A UTRN - Utrophin...
BioCentury | Oct 13, 2017
Regulation

Seeking surrogates

...a small molecule modulator of utrophin, ezutromid from Summit Therapeutics plc will face similar challenges. Utrophin...
...replaced by dystrophin as the muscle matures. He said a utrophin modulator seeks to maintain utrophin...
...muscle fibers and not on mature fibers, to identify utrophin-expressing muscle. But Roblin noted measuring utrophin...
BioCentury | May 19, 2017
Clinical News

Summit completes enrollment in Phase II DMD trial, receives $22M milestone from Sarepta

...leg muscle parameters and pharmacokinetics. Seconday endpoints will evaluate muscle regeneration biomarkers, the change in UTRN...
...24-week data in 1Q18 and top-line 48-week data in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...Product: Ezutromid (SMT C1100) (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...
BioCentury | Oct 10, 2016
Company News

Summit Therapeutics, Sarepta Therapeutics deal

...exclusive commercialization rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit’s utrophin (UTRN)...
...pipeline to treat Duchenne muscular dystrophy (DMD). The deal includes Summit’s ezutromid, a small molecule UTRN...
...million upon dosing of the last Phase II patient; and $290 million tied to additional utrophin...
BioCentury | Oct 4, 2016
Company News

Sarepta gets territorial rights to Summit's utrophin modulators

...exclusive rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin ( UTRN...
...last PhaseOut DMD patient is dosed; and $290 million tied to Summit's next-generation small molecule utrophin...
...royalties up to a high teens percentage. Starting in 2018, Summit and Sarepta will split utrophin...
Items per page:
1 - 10 of 59